Thailand Breast Cancer Therapeutics Market Report 2022 to 2030

Thailand Breast Cancer Therapeutics Market Analysis

$ 3999

Thailand's breast cancer therapeutics is expected to witness a rise in the market size from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-30 due to market drivers like changing lifestyle choices ultimately leading to breast cancer and high mortality ratios associated with breast cancer in Thailand. The market is segmented by therapy, by cancer type, and by distribution channel. ON Tanakit, Pfizer, and Bayer AG are some of the key players in the Thailand breast cancer therapeutics market.

ID: IN10THPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Parul Choudhary

Buy Now

Thailand Breast Cancer Therapeutics Market Executive Analysis

Thailand's breast cancer therapeutics is expected to witness a rise in the market size from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-30. The overall cost of healthcare in Thailand is put at $25.3 Bn. Costs are projected to increase to $47.9 Bn by 2026, which would imply a compound annual growth rate of 6.6% during the preceding ten years. With a 6.6% share of GDP, the expense of healthcare is also high. Since Thailand's Universal Coverage Scheme was initially adopted in 2002, the demand for medical services and pharmaceuticals has rapidly increased, and as a result, the Thai government now allocates around 13.3% of its total budget to public health care. Thailand has effectively put the 2030 Agenda for Sustainable Development into its Thailand 4.0 strategy and accomplished Universal Health Coverage (UHC).

Breast cancer is an increasing problem both in Thailand and around the world. It provides the ideal platform for challenging UHC and highlighting parts of the healthcare system that need to be strengthened further if UHC is to be long-term viable. Medical professionals are concerned about the rising incidence, and as breast cancer requires a multimodal therapeutic approach, an integrated response is required rather than a focus on one or a few individual interventions. The challenge also stems from Thailand's lack of uniform standards for systemic drugs, radiation, and surgical procedures. Thailand's National Breast Cancer Screening Program, which aims to boost early diagnosis of breast cancer and enhance patient outcomes, was developed by the Ministry of Public Health. Additionally, numerous hospitals in Thailand provide breast cancer treatment facilities that provide radiation therapy, chemotherapy, and procedures such as lumpectomies and mastectomies. In Thailand, there are several advanced therapeutic options including immunotherapy, hormone therapy, and targeted therapy.

Market Dynamics

Market Growth Drivers

Breast cancer is more common because of a number of variables, including genetics, a family history of the disease, early menarche or menopause, alcohol usage, obesity, and the use of specific drugs. Additionally, compared to Western nations, Thailand has substantially higher mortality-to-incidence ratios. The Thailand breast cancer therapeutics market size is expected to be driven by the disease's increasing incidence and high mortality rate.

Market Restraints

High treatment costs for breast cancer, rising prices for advanced therapeutics like hormone therapies, targeted therapies, immunotherapies, and medication adverse reactions are all anticipated to limit the growth of the breast cancer therapeutics market in Thailand.

Competitive Landscape

Key Players

OLIC (THA)
PKFB (THA)
Pure Chemicals (THA)
ON Tanakit (THA)
Pfizer
Bayer
Bipar Sciences
Astellas
Hospira
Oncogenex

Healthcare Policies and Regulatory Landscape

Through the Universal Coverage Scheme (UCS), the Ministry of Public Health (MOPH) of Thailand pays for breast cancer treatment. A variety of cancer therapies, such as surgery, radiation therapy, and chemotherapy, are covered by the UCS. However, the UCS may not fully cover more advanced therapies like targeted therapy and immunotherapy, and patients may be required to pay for some of the associated costs. The overall goals of Thailand's breast cancer reimbursement policies are to broaden patient access to care and enhance patient outcomes. However, for certain individuals, the cost of treatment and the availability of insurance for modern medicines may still be a barrier.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.